Shionogi's Pompe Trial Is a Distractor. The Real Story Is the Earnings Machine Building Underneath.

The news cycle around Shionogi this week is about a rare disease trial. The math says the real story is what the company has built underneath it.

Shionogi's S-606001 — an experimental oral therapy for late-onset Pompe disease — just enrolled its first patients in a global Phase 2 study called Esprit. The compound was acquired from Maze Therapeutics in May 2024 for $150 million upfront, with up to $605 million more in milestones. It could become the first oral substrate reduction therapy for a disease that currently depends on weekly IV enzyme replacement. That matters to Pompe patients and it matters to Shionogi's pipeline.

But this is not a binary biotech bet. Shionogi is a ¥2.6 trillion market-cap company sitting at roughly 9.4x trailing earnings, reporting first-quarter fiscal 2026 revenue that surged 63.7% year over year to ¥163.3 billion, with net income jumping 148.2% to ¥97.7 billion. The full-year 2027 guidance calls for ¥700 billion in revenue — a 40% increase on last year — and ¥220 billion in operating profit. The stock is trading well below the growth rate already embedded in the model.

The divergence between what the market sees and what the numbers show is the entire point.

Here is how Shionogi got here. Three years ago, the company was still riding the tail of pandemic-era COVID antiviral sales. Its STS2030 medium-term plan set a ¥800 billion revenue target for fiscal 2030. Management executed a series of acquisitions that turned the revenue trajectory into something real rather than aspirational.

Torii Pharmaceutical was consolidated in September 2025, adding dermatology, allergen, and dialysis products. The Japan Tobacco pharmaceutical division was absorbed in December 2025, generating a ¥43.8 billion bargain purchase gain. Akros Pharma joined the U.S. commercial team the same month. Edaravone (Radicava) global rights were acquired from Tanabe Pharma, effective April 1, 2026. Each deal added revenue, each one was paid for, and each one is now flowing through the same earnings machine.

The HIV franchise is the steady anchor. Shionogi holds a major stake in ViiV Healthcare and collects royalties plus dividends from products like Cabenuva (a long-acting HIV treatment injected once monthly) and Apretude (the long-acting PrEP injection). Royalty income from ViiV hit ¥261.3 billion in fiscal 2025, up 8.7% year over year. Dividend income from ViiV reached ¥52.4 billion, up 30%. The third-generation integrase inhibitor S-365598 is in development and could extend dosing to once every six months. This is not a one-product business; it is a royalty engine with a pipeline.

Then there is the infectious disease portfolio. Cefiderocol (Fetroja/Fetcroja), an intravenous antibiotic for multidrug-resistant Gram-negative bacteria, drove 22.9% growth in the U.S. and 23.4% in Europe during fiscal 2025. Ensitrelvir (Xocova), the oral COVID antiviral, continues to generate demand, though pandemic-driven revenue has fallen 34.8% — a normalization, not a collapse. The pipeline adds QOL disease treatments like Quviviq for insomnia, which grew 224.1% to ¥2.6 billion in one year after Japanese regulators lifted a 14-day prescription restriction, and Zurzuvae for depression, launched in March 2026.

The balance sheet backs the growth. Total assets are ¥2.58 trillion. Cash stands at ¥711 billion. The equity ratio is 65.4%. Operating cash flow was ¥213.6 billion in fiscal 2025. The company paid ¥300 billion in R&D investment over its STS Phase 2 period and still ended with cash growing nearly 90% year over year. The dividend has increased for 14 consecutive years, with the FY2026 target at ¥76 per share, yielding just under 2%.

Now put the Pompe trial in that context. S-606001 targets glycogen synthase 1 — the enzyme responsible for making glycogen — in a disease where glycogen accumulates because the body cannot break it down. Current treatments infuse replacement enzyme (ERT) to speed the breakdown. An oral SRT would attack the problem from the other direction, slowing production instead. It is a fundamentally different mechanism, and if it works as add-on therapy to ERT, it could capture meaningful share in a global Pompe market estimated at $2.1 billion in 2025, growing at roughly 9% annually.

The Phase 2 trial is 52 weeks, double-blind, placebo-controlled, enrolling across the U.S., EU, and UK. First patients were enrolled in March 2026. Top-line data will not arrive for many months. The FDA granted orphan drug designation in 2022 and rare pediatric disease designation in 2025, which means seven years of market exclusivity if approved, tax credits, and fee waivers. These are meaningful incentives, but they do not guarantee approval or commercial success.

The investment case does not rest on S-606001. It rests on a company that is growing revenue at 40% and operating profit at 32% — guided — while trading at 9.4x trailing earnings and roughly 10x on a forward basis. The company's own EPS grew 20.4% in fiscal 2025 to ¥241.11. First-quarter FY2026 EPS hit ¥114.81. Full-year FY2027 EPS is forecast at ¥246.79 based on guidance. That would put the stock at roughly 10x guided earnings on a business adding new revenue streams through acquisitions that are already consolidated and producing.

The question for investors is whether the market is pricing this as a large-cap Japanese pharma with HIV royalties and M&A-driven growth, or whether it is still anchored to the older, slower company that reported before the acquisitions hit the books. At 9.4x trailing earnings and below 11x on the FY2027 guidance EPS, the math says the market has not fully repriced.

The risks are real. Cefiderocol faces pricing pressure and competition in the antibiotic space. China revenue fell 28.3% due to generic drug cost containment. The COVID revenue decline will continue as the pandemic fades. Integration of multiple acquisitions is not automatic, and amortization of acquired intangibles will compress reported margins. The rare disease pipeline is a multi-year investment with no guarantee.

But the Pompe trial is not the headline it appears to be. The real headline is that Shionogi is executing a transformation from a mid-sized infectious disease specialist into a diversified, globally growing pharma platform — and it is doing it at a valuation that still looks like the old company. The Esprit trial is one more data point in a pipeline that gets better with each passing quarter. The earnings growth is happening now.